Werewolf Therapeutics, Inc.

NasdaqGS:HOWL Stock Report

Market Cap: US$118.9m

Werewolf Therapeutics Future Growth

Future criteria checks 2/6

Werewolf Therapeutics's earnings are forecast to decline at 23.6% per annum while its annual revenue is expected to grow at 38.1% per year. EPS is expected to decline by 7.1% per annum.

Key information

-23.6%

Earnings growth rate

-7.1%

EPS growth rate

Biotechs earnings growth28.1%
Revenue growth rate38.1%
Future return on equityn/a
Analyst coverage

Good

Last updated19 Aug 2024

Recent future growth updates

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 13
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Recent updates

Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?

Jul 31
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Jul 01

Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Jun 04
Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Apr 04

Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Feb 07
Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

Jan 19
Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Dec 09
There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Sep 30
Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 13
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

May 06
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Jan 27
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

Oct 24
We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Jul 08
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Mar 24
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Dec 09
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Earnings and Revenue Growth Forecasts

NasdaqGS:HOWL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202610-137-54N/A5
12/31/202510-102-47N/A6
12/31/20243-74-67N/A6
6/30/20249-54-42-41N/A
3/31/202416-42-39-38N/A
12/31/202320-37-33-33N/A
9/30/202326-37-41-40N/A
6/30/202325-41-50-47N/A
3/31/202321-50-40-37N/A
12/31/202216-54-44-41N/A
9/30/20229-60-45-41N/A
6/30/20224-62-41-39N/A
3/31/2022N/A-115-50-50N/A
12/31/2021N/A-202-43-43N/A
9/30/2021N/A-205-36-36N/A
6/30/2021N/A-197-29-29N/A
3/31/2021N/A-127-23-23N/A
12/31/2020N/A-28-19-19N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HOWL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HOWL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HOWL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HOWL's revenue (38.1% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: HOWL's revenue (38.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HOWL's Return on Equity is forecast to be high in 3 years time


Discover growth companies